Ustekinumab for the treatment of refractory pediatric Crohn’s disease: a single-center experience

BACKGROUND/AIMS: Despite the well-established efficacy of tumor necrosis factor (TNF) antagonists as treatment options for Crohn’s disease, many pediatric patients need a change in therapy due to adverse events and loss of response, highlighting the necessity for medications with a different mechani...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Alexandra, Ahmed, Najma, Sant’Anna, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association for the Study of Intestinal Diseases 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100375/
https://www.ncbi.nlm.nih.gov/pubmed/32312033
http://dx.doi.org/10.5217/ir.2019.09164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100375/
https://www.ncbi.nlm.nih.gov/pubmed/32312033
http://dx.doi.org/10.5217/ir.2019.09164

Ejemplares similares